Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery

BMC Ophthalmology

Research

Shu-Chun Kuo¹  Chun-Chieh Lai² 

[1] Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan;Department of Optometry, Chung Hwa University of Medical Technology, No. 901, Zhonghua Rd, Yongkang District, 710, Tainan City, Taiwan;Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan;

关键词: Dexamethasone implant;    Diabetic macular edema;    Sustained release;    Cataract;    Retinal vein occlusion;   

DOI  :  10.1186/s12886-023-03093-y

 received in 2023-03-23, accepted in 2023-07-22,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPatients with pre-existing macular edema (ME) due to diabetes and retinal vein occlusions (RVO) make up a growing population receiving cataract surgery. Surgery is associated with an increased risk of worsening existing ME due to post-surgical inflammation that can be further exacerbated by pre-existing diabetic retinopathy (DR) and retinal vein occlusion. This study aimed to examine the pre-operative use of intravitreal dexamethasone (DEX) implants in patients with ME undergoing cataract surgery.MethodsA retrospective study was conducted at National Cheng Kung University Hospital in Taiwan involving 19 eyes of 16 patients with DME or ME associated with RVO. All participants received a DEX implant at baseline and underwent phacoemulsification within 3 months after its insertion. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central subfield thickness (CST) were evaluated.ResultsDEX implants reduced the CST from baseline (357.8 μm) to pre-surgery (280.8 μm). This reduction below baseline continued to month 6 post-surgery (319.4 μm). From baseline (16.15 mmHg), the mean IOP initially increased pre-surgery (17.78 mmHg) before returning to the baseline value at month 6 post-surgery (16.15 mmHg). All patients improved their BCVA from logMAR 0.943 on average at baseline to logMAR 0.532 at month 6 post-surgery.ConclusionsThe results of the study suggested that patients with ME could benefit from DEX implants before cataract surgery within 3 months to achieve sufficient postoperative inflammation management and limit ME deterioration. DEX implants did not increase IOP post-surgery and was similar to baseline levels.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

Fig. 6

Fig. 2